Evidence map›Paper›PMID 24971702›Full record

ArticleVirology2014

The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.

Savrina Manhas, Dennis Chau, Caitlin Rempel, Brenda E Clark, Kate Auyeung, Ralph Pantophlet

Abstract read
In one paragraph

Article in Virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Savrina ManhasFaculty of Health Sciences, Simon Fraser University, British Columbia, Burnaby, Canada V5A 1S6.
Dennis ChauFaculty of Health Sciences, Simon Fraser University, British Columbia, Burnaby, Canada V5A 1S6.
Caitlin RempelFaculty of Health Sciences, Simon Fraser University, British Columbia, Burnaby, Canada V5A 1S6.
Brenda E ClarkFaculty of Health Sciences, Simon Fraser University, British Columbia, Burnaby, Canada V5A 1S6.
Kate AuyeungFaculty of Health Sciences, Simon Fraser University, British Columbia, Burnaby, Canada V5A 1S6.
Ralph PantophletFaculty of Health Sciences, Simon Fraser University, British Columbia, Burnaby, Canada V5A 1S6; Department of Molecular Biology and Biochemistry, Simon Fraser University, British Columbia, Burnaby, Canada V5A 1S6. Electronic address: rpantophlet@sfu.ca.

Funding

Exploring antibody recognition of the V3 region on HIV-1 to guide vaccine designR21AI080190 · NIAID · SIMON FRASER UNIVERSITY · PI PANTOPHLET, RALPH ALPHONSO · 2009 to 2010
$295k
NIAID NIH HHS AI080190NIAID NIH HHS R21 AI080190
6 · The paper itself

Abstract

Antibody B4e8 exhibits modest cross-neutralizing activity, with preference for HIV subtype B. This preference might be explained by B4e8׳s extensive interaction with Arg315, which occurs at the center of most subtype B V3 sequences but is replaced by Gln in subtype C. The extent to which B4e8׳s ability to neutralize subtype C strains is hindered by Gln315 and/or other factors, e.g. epitope masking, is unclear. We confirmed here that an Arg315-to-Gln substitution in a subtype B virus abrogates B4e8 neutralizing activity. Conversely, B4e8-resistant subtype C viruses were rendered sensitive upon Gln 315-to-Arg substitution. V2 region swapping between B4e8-sensitive and- resistant subtype C strains revealed a role for V2 in limiting B4e8 access, but this was less significant than the absence of Arg315. Our findings, while illustrating the importance of Arg315 for B4e8, suggest that some subtype C strains may be vulnerable to B4e8 derivatives capable of binding stronger to Gln315-containing sequences.

Indexed as

Amino Acid SubstitutionAntibodies, NeutralizingArginineenv Gene Products, Human Immunodeficiency VirusEpitopesGlutamineHIV-1HIV AntibodiesAntibodies, NeutralizingArginineenv Gene Products, Human Immunodeficiency VirusEpitopesGlutamineHIV AntibodiesAngle of interactionArg315Neutralizing antibodySubtype CV2 regionV3 masking

Identifiers

PMID24971702
PMCPMC4125615

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.